Sepracor is shelling out $75 million up front to license the marketing rights for an experimental epilepsy drug from Portugal's Bial. Sepracor will pay up to $100 million more in developmental and regulatory milestones. Release [1]
Links:
[1] http://www.fiercebiotech.com/press-releases/press-release-sepracor-license-pact-develop-antti-epileptic-compound